The regenerative medicine industry has a communication problem, and it isn’t a scientific one. The field now broadly accepts that mesenchymal stem/stromal cells (MSCs) exert their effects largely through paracrine signaling rather than engraftment and differentiation, a reframing captured in Arnold Caplan’s proposal to rename them “medicinal signaling cells.” What hasn’t matured is the public’s understanding of any of it. [Read more…]
IPS HEART’s iPSC-Derived Cell Therapy, ISX9-CPC, Secures 8th FDA Regulatory Milestone
IPS HEART Secures 8th FDA Regulatory Milestone with Rare Pediatric Drug Designation for Cardiomyopathy Associated with Muscular Dystrophies
HOUSTON–IPS HEART, Inc., a biopharmaceutical company pioneering induced pluripotent stem cell (iPSC)-derived cell replacement therapies, announced that the FDA has granted Rare Pediatric Drug Designation for ISX9-CPC, for the treatment of cardiomyopathies associated with dystrophinopathies. [Read more…]